Marksans Pharma Ltd News

Marksans Pharma hits new high; soars 30% in 1 month on healthy Q2 results

The management anticipates stronger performance in the coming quarters due to the company's upcoming new launches, the onset of the winter season and scaling up of the TEVA facility.

Marksans Pharma gets USFDA nod for allergic rhinitis treatment tablets

Marksans Pharma Ltd on Friday said it has received final approval from the US health regulator for its generic version of Loratadine tablets indicated in the treatment of allergic rhinitis. The approval by the US Food and Drug Administration (USFDA) is for the company's abbreviated new drug application (ANDA) for Loratadine tablets of strength 10 mg, Marksans Pharma said in a regulatory filing. Loratadine tablets are indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter (OTC) use. This product is a generic version of Clartin tablet in the same strength as Bayer Healthcare, the company added. Loratadine is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from "hay fever" and other allergies, it added.

Marksans Pharma shares climb after USFDA's nod for allergic rhinitis drug

Shares of Marksans Pharma gained up to 3.23 per cent at Rs 319 a piece on the BSE in Friday's intraday deals

Here's why Marksans Pharma stocks hit 52-week high on August 21; Know more

The surge in the stock price came after the company announced that its wholly owned subsidiary (WOS) Relonchem Limited has secured Marketing Authorisation from UKMHRA for three products.

Marksans Pharma stock zooms 16% to hit record high on strong Q1 results

The US & North America Formulation biz reported growth of 29.8% YoY in Q1FY25, on account of incremental revenue from new product launches, and increase in the share of existing customers.